Cargando…
Personalized prostate cancer care: from screening to treatment
Unprecedented progress has been made in genomic personalized medicine in the last several years, allowing for more individualized healthcare assessments and recommendations than ever before. However, most of this progress in prostate cancer (PCa) care has focused on developing and selecting therapie...
Autores principales: | Conran, Carly A, Brendler, Charles B, Xu, Jianfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955170/ https://www.ncbi.nlm.nih.gov/pubmed/27184548 http://dx.doi.org/10.4103/1008-682X.179529 |
Ejemplares similares
-
Population-standardized genetic risk score: the SNP-based method of
choice for inherited risk assessment of prostate cancer
por: Conran, Carly A, et al.
Publicado: (2016) -
Clinical validity and utility of genetic risk scores in prostate cancer
por: Helfand, Brian T, et al.
Publicado: (2016) -
Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases
por: Na, Rong, et al.
Publicado: (2016) -
Assessing the clinical utility of genetic risk scores for targeted cancer screening
por: Conran, Carly A., et al.
Publicado: (2021) -
SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
por: Mavrou, Athina, et al.
Publicado: (2016)